The Vaccine Gamble: High Stakes for Vaxcyte in a Crowded Field The pharmaceutical industry's relentless pursuit of innovation has led to a crowded field of vaccine developers, with Vaxcyte emerging as one of the key players.
The company's decision to pursue multiple vaccine candidates, including its flagship pneumococcal conjugate vaccine, VAX 31, raises questions about the risks and rewards of this approach.
Vaxcyte's recent second quarter results paint a picture of a company betting big on data still to come. With three Phase 3 trials for VAX 31 now fully enrolled, the first major readout is expected before year end.